Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion
- PMID: 20005397
- DOI: 10.1016/j.transproceed.2009.08.072
Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion
Abstract
Bone marrow-derived mesenchymal stem cells (MSCs) exhibit immunosuppressive functions in vitro and in vivo. We investigated the immunoregulatory effects of rat MSCs in a model of allogeneic liver transplantation. Brown Norway rats received livers from inbred Lewis rats, and at designated intervals, infusions of MSCs derived from recipient, donor, or third-party rats. Allograft rejection and recipient survival rates were recorded. In particular, changes in circulating regulatory T cells (Tregs) were measured. After administration of MSCs derived from each of the 3 strains, allograft recipients demonstrated markedly longer survival compared with control animals. Histologic analysis revealed significant inhibition of allograft rejection. The MSCs induced generation of CD4+CD25+Foxp3+ Tregs. We concluded that MSCs inhibit acute rejection of allografts after liver transplantation, and propose that the immunoregulatory effects of MSCs are associated with expansion of Tregs.
Similar articles
-
Injection of donor-derived OX62+ splenic dendritic cells with anti-CD4 monoclonal antibody generates CD4+CD25+FOXP3+ regulatory T cells that prolong allograft skin survival indefinitely and abrogate production of donor-specific antibodies in a rat model.Transplant Proc. 2009 Oct;41(8):3363-6. doi: 10.1016/j.transproceed.2009.08.038. Transplant Proc. 2009. PMID: 19857750
-
Adoptive transfusion of ex vivo donor alloantigen-stimulated CD4(+)CD25(+) regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation.Surgery. 2007 Jul;142(1):67-73. doi: 10.1016/j.surg.2007.02.014. Surgery. 2007. PMID: 17630002
-
Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model.Transplantation. 2009 Jun 27;87(12):1769-77. doi: 10.1097/TP.0b013e3181a664f1. Transplantation. 2009. PMID: 19543052
-
Bone marrow-derived mesenchymal stem cells as immunosuppressants in liver transplantation: a review of current data.Transfus Med Rev. 2012 Apr;26(2):129-41. doi: 10.1016/j.tmrv.2011.09.002. Epub 2011 Oct 19. Transfus Med Rev. 2012. PMID: 22015073 Review.
-
Mesenchymal stromal cells in renal transplantation: opportunities and challenges.Nat Rev Nephrol. 2016 Apr;12(4):241-53. doi: 10.1038/nrneph.2016.7. Epub 2016 Feb 8. Nat Rev Nephrol. 2016. PMID: 26853275 Review.
Cited by
-
Research Status of Mesenchymal Stem Cells in Liver Transplantation.Cell Transplant. 2019 Dec;28(12):1490-1506. doi: 10.1177/0963689719874786. Epub 2019 Sep 12. Cell Transplant. 2019. PMID: 31512503 Free PMC article. Review.
-
Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases.J Cell Mol Med. 2020 Jan;24(1):40-49. doi: 10.1111/jcmm.14788. Epub 2019 Nov 6. J Cell Mol Med. 2020. PMID: 31691463 Free PMC article. Review.
-
Immunomodulatory effects of adipose-derived stem cells: fact or fiction?Biomed Res Int. 2013;2013:383685. doi: 10.1155/2013/383685. Epub 2013 Sep 10. Biomed Res Int. 2013. PMID: 24106704 Free PMC article. Review.
-
Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation.Front Immunol. 2021 Feb 10;11:618243. doi: 10.3389/fimmu.2020.618243. eCollection 2020. Front Immunol. 2021. PMID: 33643298 Free PMC article. Review.
-
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.Clin J Am Soc Nephrol. 2011 Feb;6(2):412-22. doi: 10.2215/CJN.04950610. Epub 2010 Oct 7. Clin J Am Soc Nephrol. 2011. PMID: 20930086 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials